SHANGHAI - Despite the market turmoil on China’s stock exchanges since June, US-listed Chinese healthcare-related companies have not stepped back from privatization plans and the consideration of floating again on Chinese bourses, given the encouraging policies and promising development environment in the country.
The most recent privatization move was Wuxi PharmaTech’s definitive merger agreement with New Wuxi Life Science Limited and its subsidiary...